Marco Bruzzone

4.0k total citations · 1 hit paper
136 papers, 1.9k citations indexed

About

Marco Bruzzone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Marco Bruzzone has authored 136 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Marco Bruzzone's work include Organometallic Complex Synthesis and Catalysis (14 papers), Breast Cancer Treatment Studies (11 papers) and Polymer Nanocomposites and Properties (10 papers). Marco Bruzzone is often cited by papers focused on Organometallic Complex Synthesis and Catalysis (14 papers), Breast Cancer Treatment Studies (11 papers) and Polymer Nanocomposites and Properties (10 papers). Marco Bruzzone collaborates with scholars based in Italy, Belgium and United States. Marco Bruzzone's co-authors include Marcello Ceppi, Matteo Lambertini, Evandro de Azambuja, Lucia Del Mastro, Francesca Poggio, Noam Pondé, Giovanni La Valle, Elisa Agostinetto, Michael Fenech and Claudia Bolognesi and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Marco Bruzzone

129 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

2018 303 citations Francesca Poggio, Marco Bruzzone et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marco Bruzzone Italy	24	707	413	320	276	203	136	1.9k
Chia‐Hung Chou Taiwan	29	661 0.9×	301 0.7×	137 0.4×	1.1k 3.8×	328 1.6×	84	3.0k
Sarah A. Taylor United States	25	835 1.2×	146 0.4×	407 1.3×	453 1.6×	477 2.3×	146	2.6k
Li Song China	26	295 0.4×	174 0.4×	279 0.9×	503 1.8×	271 1.3×	117	2.0k
David Köhler United States	25	797 1.1×	317 0.8×	427 1.3×	720 2.6×	114 0.6×	63	2.4k
Corrado Ficorella Italy	27	1.2k 1.6×	419 1.0×	651 2.0×	584 2.1×	273 1.3×	140	2.6k
Kamal S. Saini United States	24	1.2k 1.7×	485 1.2×	327 1.0×	697 2.5×	130 0.6×	88	2.4k
Michael Hayes United States	33	574 0.8×	131 0.3×	488 1.5×	1.2k 4.2×	161 0.8×	97	4.1k
Katherine H. R. Tkaczuk United States	21	1.8k 2.5×	968 2.3×	387 1.2×	436 1.6×	175 0.9×	47	2.8k
D Belpomme France	23	710 1.0×	313 0.8×	317 1.0×	508 1.8×	181 0.9×	102	2.5k
Miao Mo China	24	526 0.7×	563 1.4×	493 1.5×	672 2.4×	276 1.4×	96	2.0k

Countries citing papers authored by Marco Bruzzone

Since Specialization

Citations

This map shows the geographic impact of Marco Bruzzone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Bruzzone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Bruzzone more than expected).

Fields of papers citing papers by Marco Bruzzone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Bruzzone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Bruzzone. The network helps show where Marco Bruzzone may publish in the future.

Co-authorship network of co-authors of Marco Bruzzone

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Bruzzone. A scholar is included among the top collaborators of Marco Bruzzone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Bruzzone. Marco Bruzzone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2025). Prognostic implications of risk definitions from the monarchE and NATALEE trials. JNCI Journal of the National Cancer Institute. 117(6). 1198–1208. 3 indexed citations

Molinelli, Chiara, Marco Bruzzone, Eva Blondeaux, et al.. (2024). The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. 213. 115113–115113. 4 indexed citations

Debien, Véronique, Elisa Agostinetto, Marco Bruzzone, et al.. (2024). The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial. Clinical Breast Cancer. 24(5). 421–430.e3. 6 indexed citations

Hamy, Anne‐Sophie, Sabine C. Linn, Rinat Bernstein‐Molho, et al.. (2024). 266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study. ESMO Open. 9. 103325–103325.

Tagliamento, Marco, Marco Bruzzone, Marcello Ceppi, et al.. (2023). 186P Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials. Annals of Oncology. 34. S255–S256. 1 indexed citations

Boutros, Andrea, Enrica T. Tanda, Fabio Catalano, et al.. (2023). Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. European Journal of Cancer. 188. 64–79. 24 indexed citations

Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2022). Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Human Reproduction. 37(5). 954–968. 61 indexed citations

Tagliamento, Marco, Elisa Agostinetto, Marco Bruzzone, et al.. (2021). Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 163. 103365–103365. 44 indexed citations

Mencoboni, Manlio, Marcello Ceppi, Marco Bruzzone, et al.. (2021). Effectiveness and Safety of Immune Checkpoint Inhibitors for Patients with Advanced Non Small-Cell Lung Cancer in Real-World: Review and Meta-Analysis. Cancers. 13(6). 1388–1388. 26 indexed citations

10.

Boutros, Andrea, Marco Bruzzone, Enrica T. Tanda, et al.. (2021). 1687P Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomized controlled trials: A systematic review and meta-analysis. Annals of Oncology. 32. S1180–S1181. 1 indexed citations

11.

Lambertini, Matteo, Francesca Poggio, Marco Bruzzone, et al.. (2019). Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. International Journal of Cancer. 147(1). 160–169. 11 indexed citations

12.

Lambertini, Matteo, Marco Bruzzone, Francesca Poggio, et al.. (2019). The role of dose-dense (DD) adjuvant chemotherapy (CT) in HER2-positive (HER2+) early breast cancer (BC) patients (pts) before and after the introduction of trastuzumab (T): Exploratory analysis of the GIM2 trial. Annals of Oncology. 30. iii28–iii28. 1 indexed citations

13.

Merlo, Domenico Franco, Marco Bruzzone, Paolo Bruzzi, et al.. (2018). Mortality among workers exposed to asbestos at the shipyard of Genoa, Italy: a 55 years follow-up. Environmental Health. 17(1). 94–94. 12 indexed citations

14.

Poggio, Francesca, Marco Bruzzone, Marcello Ceppi, et al.. (2018). Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open. 3(4). e000361–e000361. 47 indexed citations

15.

Ciprandi, Giorgio, et al.. (2017). Serum allergen-specific IgE, allergic rhinitis severity, and age. Rhinology Journal. 54(3). 231–238. 10 indexed citations

16.

Martel, Samuel, Marco Bruzzone, Marcello Ceppi, et al.. (2017). Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 62. 123–132. 17 indexed citations

17.

Bolognesi, Claudia, Marco Bruzzone, Marcello Ceppi, & Micheline Kirsch‐Volders. (2017). The lymphocyte cytokinesis block micronucleus test in human populations occupationally exposed to vinyl chloride: A systematic review and meta-analysis. Mutation Research/Reviews in Mutation Research. 774. 1–11. 13 indexed citations

18.

Ciprandi, Giorgio, et al.. (2016). Serum allergen-specific IgE, allergic rhinitis severity, and age. Rhinology Journal. 54(3). 231–238. 25 indexed citations

19.

Deferrari, Giacomo, Giacomo Garibotto, Cristina Robaudo, et al.. (2015). Renal Ammoniagenesis and Interorgan Flow of Glutamine in Chronic Metabolic Acidosis. Contributions to nephrology. 110. 144–149. 1 indexed citations

20.

Gadducci, Angiolo, I. Brunetti, Marco Bruzzone, et al.. (1992). Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).. PubMed. 13(1 Suppl). 36–9. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact